A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.
← catalyst calendarSponsored by LG Chem (industry) · 051910.KS — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Other
Enrollment
58actual
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-09 | actual | When the study began enrolling |
| Primary completion | 2026-02-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-06 | actual | The whole study's end, after follow-up |
| First posted | 2026-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Fasting Conditions
Interventions
- Drug: Test drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg
- Drug: Reference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin/metformin (Xigduo XR) 10/1000 mg
Primary outcomes
what the primary-completion date above is the date OFThe plasma concentration of Gemigliptin, Dapagliflozin and Metformin
measured Up to 72 hours
The plasma concentration of Gemigliptin, Dapagliflozin and Metformin
measured Up to 72 hours
Permalink · 051910.KS's whole pipeline · Catalyst calendar · Every registered study · What changed